Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma

doi:10.3748/wjg.v11.i30.4655

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 30

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3086)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

311

HTML

2325

Figures (1-2)

212

Tables (1-4)

238

Sum=3086

Aug 14, 2005 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (32)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Aug 14, 2005; 11(30): 4655-4660
Published online Aug 14, 2005. doi: 10.3748/wjg.v11.i30.4655

Table 1 Alterations of total RNA (mean±SD) and amplification of IGF-II mRNA in cancerous, para-cancerous, and non-cancerous liver tissues

Groups	n	Total RNA level(μg/mg wet tissue)	IGF-II mRNA
Groups	n	Total RNA level(μg/mg wet tissue)	Positive	%
Cancerous tissues	30	13.4 ± 8.4	30	100
Para-cancerous tissues	30	20.7 ± 14.6^a	16	53.3^b
Non-cancerous tissues	30	25.0 ± 20.2^b	0	0^b

^aP<0.05,

^bP<0.01 vs the cancerous tissue group.

Table 2 Levels of serum free IGF-II and AFP in patients with chronic liver diseases

Groups	n	Free IGF-II (μg/L)		AFP (μg/L)
Groups	n	mean±SD	> 6.0 (%)	mean±SD	> 50 (%)
CH	30	4.1 ± 2.4	8 (26.7)	32.0 ± 23.7	7 (23.3)
LC	25	5.5 ± 1.7	7 (28.0)	34.7 ± 39.8	9 (36)
HCC	111	6.7 ± 1.8	84 (75.7) ^b	417.5 ± 274.1	72 (64.9) ^b

^bP<0.01 vs the chronic hepatitis group or the liver cirrhosis group. HCC: hepatocellular carcinoma; LC: liver cirrhosis; CH: chronic hepatitis.

Table 3 Analysis of IGF-II-mRNA and AFP-mRNA in peripheral blood of patients with different liver diseases or non-liver tumors

Groups	n	IGF-II mRNA		AFP mRNA		Both
Groups	n	Positive	%	Positive	%	Positive	%
HCC	111	38	34.2	58	52.3	68	61.3
LC	25	0	0^b	5	20.0^b	5	20.0^b
CH	30	0	0^b	2	6.7^b	2	6.7^b
AH	30	0	0^b	0	0^b	0	0^b
ET	25	0	0^b	0	0^b	0	0^b
NC	25	0	0^b	0	0^b	0	0^b

^bP<0.01 vs the hepatocellular carcinoma group. HCC: hepatocellular carcinoma; LC: liver cirrhosis; CH: chronic hepatitis; AH: acute hepatitis; ET: extrahepatic tumor; NC: normal control.

Table 4 Relationship between peripheral blood IGF-II mRNA or AFP mRNA and HCC stage or metastasis

Groups	n	IGF-II mRNA		AFP mRNA
Groups	n	Positive	%	Positive	%
HCC Stage I	14	2	14.3^a	5	35.7^a
Stage II	31	6	19.4^a	8	25.8^a
Stage III	66	30	45.5	47	71.2
Intra-hepatic metastasis
With	67	27	40.3	44	65.7^c
Without	44	11	25	18	40.9
Extrahepatic metastasis
With	13	13	100^b	13	100^b
Without	98	25	25.5	53	54.1

^aP<0.05 vs the HCC stage III group.

^bP<0.01,

^cP<0.05 vs the non-metastasis group. HCC: hepatocellular carcinoma.

Citation: Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11(30): 4655-4660
URL: https://www.wjgnet.com/1007-9327/full/v11/i30/4655.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i30.4655